AR and Familial prostate cancer: Given the relative poor efficacy of cyclin D1b in titering AR function, high cyclin D1b expression may render a mechanism whereby prostate cancer cells may promote CDK4 activity (and/or other pro-proliferative targets utilized by cyclin D1b) while concurrently evading mechanisms to modulate the AR dependent growth response.